# US 2026/0076943 A1 · Method for improving skeletal health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076943 A1
- Document ID: US20260076943A1
- Status: Published application
- Kind: A1
- Application number: 19/333,029
- Filed: 2025-09-18
- Published: 2026-03-19
- Earliest claimed: 2024-09-19
- Assignees: The Trustees of Indiana University
- Applicants: The Trustees of Indiana University
- Inventors: Keith Gerard Avin; Sharon Moe; Michael L. Schulte
- Web page: https://patentgrep.com/patent/US20260076943A1

## CPC

- A61K 31/415: 1,2-Diazoles
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to an alternative intervention to improve skeletal muscle health in chronic kidney disease (CKD). CKD causes skeletal muscle complications that lead to increased risk of falls, hospitalizations and mortality. While exercise is a common treatment for these impairments in the general population, in patients with CKD exercise has shown only marginal improvements in aerobic capacity and inconsistent effects on muscle strength, walking distance, and timed-up-and-go tests indicating this ‘usual’ treatment is not enough in patients in CKD. The present disclosure relates to methods of using an aminoindazole to treat inflammation and metabolic derangements and to improve skeletal muscle health in CKD.

## Claims

### Claim 1

A method of improving skeletal health and/or muscle function in a patient experiencing muscle wasting, the method comprising:
administering a therapeutically effective amount of an aminoindazole, or a pharmaceutically acceptable salt thereof, to the patient in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aminoindazole is locamidazole, or a pharmaceutically acceptable salt thereof, or linifanib, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method improves the handgrip strength, the sit-to-stand test, the 6-minute walk test, the timed up and go test, the gait speed, the isometric knee extensor strength, the short physical performance battery scores, or a combination thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the improvement of muscle function is muscle strength and/or muscle fatigue.

### Claim 5 (depends on 2)

The method of claim 2, wherein the method improves skeletal health by increasing bone cortical thickness and/or porosity.

### Claim 6 (depends on 2)

The method of claim 2, wherein the method downregulates inflammatory pathways.

### Claim 7 (depends on 6)

The method of claim 6, wherein the method reduces PTH levels.

### Claim 8 (depends on 2)

The method of claim 2, wherein the method normalizes macrophage expression.

### Claim 9 (depends on 2)

The method of claim 2, wherein the method reduces macrophage infiltration in skeletal muscle.

### Claim 10 (depends on 2)

The method of claim 2, wherein the method upregulates a gene in a metabolic pathways, improves fatty acid uptake and esterification, or both.

### Claim 11 (depends on 10)

The method of claim 10, wherein the metabolic pathway is selected from the group consisting of fatty acid oxidation, ATP synthesis, and the electron transport chain.

### Claim 12 (depends on 2)

The method of claim 2, wherein the method improves mitochondrial morphology.

### Claim 13 (depends on 12)

The method of claim 12, wherein the improved mitochondrial morphology comprises reduced mitochondrial swelling and/or reduced disorganization of mitochondrial cristae.

### Claim 14 (depends on 2)

The method of claim 2, wherein mitochondria impairment is decreased when compared to a patient not receiving the aminoindazole.

### Claim 15 (depends on 2)

The method of claim 2, wherein the aminoindazole is locamidazole, or a pharmaceutically acceptable salt thereof.

### Claim 16

A method of improving skeletal health and/or muscle strength in a patient having chronic kidney disease, the method comprising:
administering a therapeutically effective amount of an aminoindazole, or a pharmaceutically acceptable salt thereof, to the patient in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the aminoindazole is locamidazole, or a pharmaceutically acceptable salt thereof, or linifanib, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the aminoindazole is administered in combination with an additional therapeutic.

### Claim 19 (depends on 17)

The method of claim 17, wherein the additional therapeutic is a GLP-1 inhibitor, or an anti-inflammatory drug.

### Claim 20 (depends on 16)

The method of claim 16, wherein the patient has an amyotrophic disease.
